Lucid Diagnostics is developing a revolutionary non-invasive, office based diagnostic test for biomarkers to esophageal cancer.
Mentions in press and media 16
| Date | Title | Description |
| 13.09.2024 | The Battle Against Esophageal Cancer: A New Era of Early Detection | Esophageal cancer is a silent predator. It lurks in the shadows, often undetected until it’s too late. However, a new dawn is breaking in the fight against this formidable foe. Lucid Diagnostics Inc. is stepping into the spotlight, armed wi... |
| 10.09.2024 | Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress | Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company&q... |
| 03.09.2024 | Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health | Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luci... |
| 15.08.2024 | PAVmed's Path to Progress: A Dual Focus on Financial Stability and Cancer Prevention | PAVmed Inc. is navigating the complex waters of the medical technology industry. With a focus on diagnostics and digital health, the company is not just a player; it’s a contender. Recent updates reveal a dual strategy: enhancing financial ... |
| 13.08.2024 | PAVmed Provides Business Update and Second Quarter 2024 Financial Results | Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing following launch of pilot program with ... |
| 13.08.2024 | The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer | Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"... |
| 06.08.2024 | Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing | Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" ... |
| 23.07.2024 | Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume | Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK, July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical di... |
| 02.07.2024 | Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population | Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA screening study also accepted for peer-reviewed ... |
| 12.06.2024 | 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing | Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK, June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or t... |
Show more